JBJ-03-142-02

Key Product Details

Product Description

JBJ-03-142-02 is a highly potent epidermal growth factor receptor (EGFR) and ErbB2 (human epidermal growth factor receptor; HER2) inhibitor. Inhibits wild type and tumorgenic mutated receptors (exon 20 insertion; Ex20Ins). Antiproliferative in vitro (IC₅₀ values are 7.6, 30 - 95, 3.8 and 19 - 31 nM for Ba/F3 cells expressing wild type EGFR, EGFR with Ex20Ins mutation, wild type HER2 and HER2 with Ex20Ins mutation, respectively). Also inhibits other common EGFR mutants. Antiproliferative in patient-derived lung cancer cell lines.

Licensing Information

Sold under license from Dana-Farber Cancer Institute

Product Specifications for JBJ-03-142-02

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for JBJ-03-142-02

The following data is based on the product molecular weight 487.50.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.10 mL	20.51 mL	41.03 mL
2.5 mM	0.82 mL	4.10 mL	8.21 mL
5 mM	0.41 mL	2.05 mL	4.10 mL
25 mM	0.08 mL	0.41 mL	0.82 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Jang Discovery of a highly potent and broadly effective epidermal growth factor receptor and HER2 exon 20 insertion mutant inhibitor. Angew.Chem.Int.Ed.Engl. 2018 PMID: 29978938

Product Documents for JBJ-03-142-02